IFI44L and neoplasm: A total of 44/70 immunomodulators in the TCGA-LUAD cohort and 57/70 immunomodulators in the TCGA-LUSC cohort presented significant correlation with the transcript level of IFI44L. As reported, the immunomodulators have tremendous and abundant functions in the TME, as well as tumor development and progression (35, 36).